AI Pathology Model Validated Across Triple-Negative and HER2+ Breast Cancer Subtypes
kjgeras · x · 2026-07-06
Unlike existing genomic tests primarily designed for HR+/HER2-, this AI test performs effectively across all major breast cancer subtypes, including triple-negative (C-index 0.71) and HER2+ (C-index 0.67). Currently, there are no guideline-supported prognostic or predictive tests for these two subtypes.
More from Research
- TRL adds Score Centering, a simple fix for RLHF training instability — lvwerra · 2026-10-27
- Latent-Foresight: world models that learn to predict their own future — abursuc · 2026-10-27
- UK AISI papers: no good safeguards yet against misuse of biological AI tools — davidmanheim · 2026-10-27
- CMU's XYBench: LLMs answer queries literally and reinforce user misconceptions — valentina__py · 2026-10-27
- arXiv advice from T. Dietterich: wrong primary category will almost surely get your paper on hold — tdietterich · 2026-10-27
- arXiv has 4,000+ papers on hold amid submission surge; moderator shares how to avoid it — tdietterich · 2026-10-27